Featured Posts
Blog
Trump administration decision highlights disastrous Part D redesign
The Trump administration recently announced the end of a demonstration project that was pulled together by the Biden administration as the Inflation Reduction…
Study
A Free Market is the Best Medicine
Introduction The pharmaceutical supply market is seeing extraordinarily high levels of innovation and consumer-benefiting evolution. The combination of a competitive market for generic drugs,…
Blog
Congress considers micromanaging PBM finances
With the first reconciliation bill behind it, Congress is now looking to reform other aspects of the health care system. Pharmacy Benefit Manager…
Search Posts
Products
Gregory Conko Discussing Cloning Translating Into Big Business and Safety Issues on CNNfn
CNNfn: Money & Markets (c) 2003 Federal Document Clearing House. All Rights Reserved. Friday, October 31, 2003 Business Cloning Translating Into Big Business and Safety…
Study
Safety, risk and the precautionary principle: rethinking precautionary approaches to the regulation of transgenic plants
Full Document Available in PDF Ever since completion of the Cartagena Protocol on Biosafety in…
Legal Brief
Memorandum Opinion in Association of Physicians and Surgeons vs US FDA
Comment
Comments Regarding the Constitutionality of FDA Treatment of Product Information
This request for comments represents a welcome departure from FDA’s prior treatment of First Amendment concerns in the context of product advertising, labeling, and promotions.
Study
Hidden Truth: The Perils and Protection of Off-Label Drug and Medical Device Promotion
Full Document Available in PDF What can you do if you learn you have a life-threatening…
News Release
CEI Slams FDA Vote on Avastin
Washington, D.C., June 29, 2011 — An FDA advisory committee voted today to revoke the approval for breast cancer treatment from the drug Avastin.